Fred Alger Management’s Nektar Therapeutics NKTR Stock Holding History

Fred Alger Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35M	Sell	33,673 -19,499	-37%	-$1.43M	0.01%	303
2026 Q1	$3.83M	Sell	53,172 -848	-2%	-$48.3K	0.02%	253
2025 Q4	$2.28M	Sell	54,020 -37,787	-41%	-$2.11M	0.01%	304
2025 Q3	$5.22M	Buy	91,807 +39,096	+74%	+$1.29M	0.02%	236
2025 Q2	$1.36M	Buy	52,711 +18,948	+56%	+$213K	0.01%	339
2025 Q1	$344K	Buy	+33,763	New	+$441K	﹤0.01%	380
2018 Q2	–	Sell	-67	Closed	-$106K	–	571
2018 Q1	$106K	Buy	+67	New	+$86.3K	﹤0.01%	406
2016 Q3	–	Sell	-2,667	Closed	-$569K	–	529
2016 Q2	$569K	Sell	2,667 -9,287	-78%	-$2.08M	﹤0.01%	372
2016 Q1	$2.46M	Sell	11,954 -8,239	-41%	-$1.58M	0.01%	312
2015 Q4	$5.1M	Buy	+20,193	New	+$4.15M	0.02%	248

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fred Alger Management's NKTR Position: Q2 2026 in Review

Fred Alger Management reduced its Nektar Therapeutics (NKTR) stake by 37% in Q2 2026, selling an estimated $1.43M and leaving 33,673 shares worth $2.35M. The position accounts for 0.01% of the portfolio, ranked #303.

Fred Alger Management first reported a position in NKTR in Q4 2015 and has held it in 10 quarters since. The position peaked at $5.22M in Q3 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Fred Alger Management held 33,673 shares of Nektar Therapeutics worth $2.35M as of Q2 2026.
Fred Alger Management sold 19,499 Nektar Therapeutics shares in Q2 2026, an estimated $1.43M.
Nektar Therapeutics made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #303 holding.
Fred Alger Management first reported a position in Nektar Therapeutics in Q4 2015 and has held it in 10 quarters since.
Fred Alger Management's Nektar Therapeutics position peaked at $5.22M in Q3 2025.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.